Peer-reviewed veterinary case report
Effectiveness and safety of CredelioPlus for preventing heartworm
By Young, Lisa M et al.·Published in Parasites & vectors·2021·Elanco Animal Health Research and Development, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (CredelioPlus) for the prevention of heartworm disease (Dirofilaria immitis) in client-owned dogs in the USA.
- Species:
- dog
Plain-English summary
A group of dogs in the USA, all confirmed to be free of heartworm, were given a new chewable tablet called CredelioPlus, which combines two medications, milbemycin oxime and lotilaner, to prevent heartworm disease. Over 11 months, these dogs were monitored, and at the end of the study, none of them tested positive for heartworm, showing that the treatment was 100% effective. The dogs tolerated the medication well, with no safety issues reported. This means that CredelioPlus is a safe and effective option for preventing heartworm in dogs.
People also search for: heartworm prevention for dogs · CredelioPlus for heartworm · dog heartworm treatment options
Abstract
BACKGROUND: Dirofilaria immitis, a globally distributed filarial parasite of dogs, is known to cause serious or fatal cardiopulmonary disease. Client-owned dogs were enrolled in a clinical field study in the USA to evaluate the clinical effectiveness and field safety of an orally administered combination investigational product (IP) containing milbemycin oxime and lotilaner (CredelioPlus) as compared to a control product (CP) for the prevention of heartworm disease when administered monthly for 11 consecutive months. METHODS: In this 11-month field study, 319 dogs ≥ 8 weeks old confirmed to be heartworm-negative were enrolled from eight geographically distinct US veterinary clinics, including sites in the southern USA and Mississippi River Valley. The dogs were treated with either the IP combination product at 0.75-1.53 mg/kg milbemycin oxime and 20-41.5 mg/kg lotilaner (n = 159) or the CP (SentinelFlavor Tabs; milbemycin oxime/lufenuron) at the label-recommended dose rate (n = 158.) On day 330, effectiveness was evaluated in each dog using antigen and microfilarial (modified Knott's) testing to assess the establishment of any patent adult heartworm infections. RESULTS: All dogs treated with the IP combination product and the CP tested negative (100% prevention) for heartworm infection on day 330. The IP combination product tablets containing milbemycin oxime and lotilaner were well tolerated based on the safety assessments in all treated dogs. CONCLUSIONS: This multi-site clinical study using client-owned dogs demonstrated that monthly use of flavored, chewable tablets containing a combination of milbemycin oxime and lotilaner administered orally under end use conditions is safe for dogs. None of the enrolled dogs developed heartworm infections. Eleven consecutive monthly treatments of the IP provided 100% prevention of heartworm disease caused by D. immitis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34044864/